Our hypothesis was to employ the L-type calcium channel blocker, nifedipine (NFD), for tackling pulmonary fibrosis via interfering with the calcium influx to fibroblasts through suppressing the effect of TGF-β1. Here, TGFB1 is linked to pulmonary fibrosis.